Opens in a new tab
For licensed clinics onlyRefrigerated lines shipped cold
1-800-630-9757Open hoursMonday to Friday, 9am to 6pm ETBook a call with MWS
1 vialFor licensed clinicsIn stock

Order ARA-290 for Clinics

ARA-290 (cibinetide)

Free shipping on orders over $800

5% off your first order, applied at checkout

QuantityPrice per vial
This option is currently unavailable. Please choose another.
Treatment cost and margin plannerPlanning tool

Enter your own figures: the vials you use per treatment and what you charge per treatment. The table shows your product cost and margin per treatment at each quantity price. It does not suggest doses, prices or treatments.

QuantityPrice per packCost per unitCost per treatmentMargin per treatment

Uses today's prices for the selected option before shipping and any other costs. Your figures stay in your browser.

  • Ships within 24–48 hours

    Delivery typically 48–72 hours after shipping, up to 5–7 business days depending on origin and customs. Tracking is emailed when your order ships.

  • Warm or damaged on arrival?

    Send us photos or a video. We investigate and arrange a replacement where needed.

  • Licence checks

    Licences are checked against the state board and the NPI registry.

  • 100% genuine products

    In original manufacturer packaging, with lot numbers for full traceability. Lot numbers are shown on your packing slip and invoice.

Rated 5/5 by our clinic customers

250 active clinics · Supplying clinics since 2013

“Everything has been easy from ordering to delivery. The prices are good, orders arrive quickly, and the customer service has been great. I would definitely order from MWS again.”
Alex B., NP
We acceptVisa, Mastercard and American Express

Customer service team

Monday to Friday, 9am to 6pm ET

ARA-290 14mg

$85.00
You save

Add to order

Specifications at a glance

Generic name
ARA-290 (cibinetide)
Package content
1 vial
Main ingredient
Peptides
Who can order
For licensed clinics and healthcare professionals.

About ARA-290 14mg

ARA-290 (also known by its investigational name cibinetide) is a synthetic 11-amino-acid peptide derived from the tissue-protective helix-B region of erythropoietin (EPO). It was engineered to retain EPO’s anti-inflammatory and tissue-protective signaling while removing the erythropoietic activity that stimulates red blood cell production. It is used in professional and laboratory settings where researchers are evaluating inflammation, nerve repair, or related investigational workflows. Licensed clinics and research accounts can order ARA-290 for practice or laboratory use, with careful attention to professional documentation, form verification, storage, and safety review. It has no FDA-approved human indication for general use, so accounts should treat ARA-290 as an investigational research peptide rather than a retail wellness supplement.

Before adding ARA-290 to inventory, define who will evaluate the product, how it fits the research or clinic protocol, and what records must be retained for purchasing, receipt, storage, and use. Product names in the broader market may refer to powders, lyophilized vials, or reconstituted solutions, but the account should match the active ingredient, quantity, sterility status, and packaging to the current item record before use.

How Clinics and Labs Can Order ARA-290

Ordering ARA-290 should begin with a professional-use or research-use assessment, not a consumer-style purchase. The account should identify the medical director, principal investigator, or supervising professional responsible for product evaluation, the staff member responsible for receiving inventory, and the internal protocol that explains why the peptide is being considered.

MedWholesaleSupplies serves licensed clinical and research accounts, so account records and practice-use context may be reviewed before an order proceeds. For broader peptide procurement, the Peptides category can help teams evaluate adjacent items, but each peptide still requires its own individual review.

Risk Framework and Safety Considerations

Questions about ARA-290’s effects in humans cannot be answered from approved labeling because there is no FDA-approved human label for general use. ARA-290 has been evaluated in Phase 2 human trials for sarcoidosis-associated small fiber neuropathy and diabetic neuropathy, and holds FDA orphan drug designation for the former, but development has not progressed to approval and its original sponsor ceased operations. Accounts should use a conservative risk framework, especially for any research involving live subjects, and should have institutional review or biosafety oversight in place before proceeding.

Why it matters: Phase 2 trial signals and orphan-drug designation do not replace informed consent (where applicable), institutional review, or adverse-event planning.

Forms, Strengths, and Product Verification

ARA-290 is marketed across the wider peptide space using terms such as ARA-290 powder, ARA-290 vial, cibinetide, ARA-290 14mg, and reconstituted ARA-290. Those descriptions should not be treated as confirmation of the format available for this item. The account should verify the active ingredient, form, quantity, purity (HPLC/COA), sterility status, and packaging against the current product record and supplier documents.

Storage, Handling, and US Logistics

Storage instructions should come from the product label, certificate of analysis, or distributor documentation. Peptides may be sensitive to heat, light, moisture, or reconstitution technique, so accounts should avoid assumptions based on another brand, compound, or market format.

Receiving staff should inspect packaging before releasing ARA-290 into inventory. Match the item to the purchase record, record lot and expiry information, note package condition, and place the product in the required storage environment (typically frozen or refrigerated, protected from light). For operational planning, accounts should factor in temperature-controlled handling and tracked US delivery requirements.

Related Peptides

Accounts evaluating ARA-290 alongside related tissue-repair or anti-inflammatory research compounds, or other investigational peptides in the Peptides category, should assess each item separately — combination or comparative research still requires individual documentation, sourcing verification, and risk review for every active ingredient involved.

Questions clinics ask

Licensed clinics, research accounts, and healthcare professionals can order ARA-290 for practice or laboratory use after completing the required account and professional-use review. The account should define responsible staff, retain product records, and document how the peptide fits its internal protocol.

ARA-290 is not FDA-approved for general human use. It holds orphan drug designation for sarcoidosis-associated small fiber neuropathy and has been studied in Phase 2 trials, but accounts should treat it as an investigational compound and avoid patient-facing claims that imply proven or approved treatment outcomes.

Market listings may describe ARA-290 as powder, lyophilized vials, or reconstituted solution, sometimes under its research name cibinetide. Accounts should verify the actual form, strength, quantity, purity documentation (COA), sterility status, and storage requirements shown for the current product record.

MWS Customer Service Team

Ordering in volume or opening a clinic account? Talk to us.

Our customer service team helps you choose the right pack, label option and quantity for your clinic, and sets up your first order.

Monday to Friday, 9am to 6pm ET

Why clinics order from MWS

  • Built for licensed clinics

    Licences are checked against the state board and the NPI registry.

  • Every pack option named

    Each option names its dosage and pack size, so you know which pack you are ordering.

  • Volume pricing up front

    Quantity tiers are shown on the product, before you order.

  • Cold-chain packing

    Refrigerated lines ship in thermo-packaging with enough ice packs to hold temperature for up to 10 days.

“The customer care team was very efficient in offering hand-held guidance to choose the most cost-effective options.”
Dr Tukba Yalcin, Lumiere Aesthetics

Related reading